Clinical Trial

Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.

Study acronym: ALTHBV
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 1, 2024 (before its estimated June 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus DNA.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-01-15; most recent amendment 2024-02-28.
Trial Details
NCT Number NCT04231565
Lead Sponsor Third Affiliated Hospital, Sun Yat-Sen University
Conditions Hepatitis B Virus
Enrollment 200 participants
Start Date 2020-06-04
Primary Completion 2024-06-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2024-03-01